Abiraterone acetate for men with metastatic disease and a sub-optimal response to ADT

Posted on May 6, 2013 by Sitemaster

The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a Comment »

Drug sequencing and combination therapy with newer prostate cancer therapies

Posted on April 17, 2013 by Sitemaster

There is an interesting report on the OncLive web site of a lecture by Dr. Robert Dreicer given just a few weeks ago and dealing with the sequential and combination use of new agents like abiraterone acetate, enzalutamide and others for the treatment of advanced and progressive forms of prostate cancer. … READ MORE …

Filed under: Management, Living with Prostate Cancer, Treatment, Drugs in development | Tagged: , , , , , | 14 Comments »

Statins in clinical trials for advanced forms of prostate cancer

Posted on April 10, 2013 by Sitemaster

An editorial  by Freeman and Solomon (“Statin drugs and prostate cancer: time to consider proactive strategies in patients“) in the April issue of the Journal of Urology has proposed the idea of combining abiraterone acetate with a statin as a method to treat men with castration-resistant prostate cancer (CRPC). … READ MORE …

Filed under: Management, Living with Prostate Cancer, Treatment, Drugs in development | Tagged: , , , | Leave a Comment »

New data on new and newer drugs at the GU Cancers meeting

Posted on February 14, 2013 by Sitemaster

A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , , , | 6 Comments »

Brain metastasis, new drugs, and future treatment of mCRPC

Posted on January 14, 2013 by Sitemaster

A new article on the Medcape Oncology web site discusses progress in the treatment of metastatic, catsration-resistant prostate cancer (mCRPC) and the specific relationship between risk for brain metastasis and the extension of overall survival. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | Leave a Comment »

Zytiga approved in Europe for chemotherapy-naive mCRPC

Posted on January 14, 2013 by Sitemaster

As in the USA and some other countries, the European Union has now approved abiraterone acetate (Zytiga®), in combination with prednisone or prednisolone, for the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 3 Comments »

Abiraterone acetate in chemotherapy-naive mCRPC: full data published

Posted on January 10, 2013 by Sitemaster

An article published this week in the New England Journal of Medicine gives the full results of the Phase III trial of abiraterone acetate + prednisone in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). These data were originally reported at the ASCO annual meeting in 2011. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 6 Comments »

Overall survival among chemo-naive, mCRPC patients in the abiraterone acetate Phase III trial

Posted on December 15, 2012 by Sitemaster

There appears to be a great deal of confusion about the overall survival (OS) data related to the recent approval of abiraterone acetate for chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). Let’s try to really clarify this. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 4 Comments »

Data from trial of abiraterone in chemo-naive mCRPC published in NEJM

Posted on December 13, 2012 by Sitemaster

This week’s issue of the New England Journal of Medicine (NEJM) carries the full report of the results of the so-called COU-AA-302 trial of abiraterone + prednisone vs. a placebo + prednisone in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 7 Comments »

FDA approves abiraterone acetate for chemotherapy-naive mCRPC

Posted on December 10, 2012 by Sitemaster

According to an announcement earlier today, the U. S. Food and Drug Administration (FDA) has approved an expanded indication for abiraterone acetate (Zytiga®) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), inclusive of patients who have not received any form of chemotherapy. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 12 Comments »

CMPH recommends expanded indication for abiraterone in mCRPC … before chemotherapy

Posted on November 16, 2012 by Sitemaster

According to a summary statement of opinion issued yesterday by the Committee for Medicinal Products for Human Use (CMPH) of the European Mediciens Agency (EMEA), CMPH is recommending an expanded indication for the clinical use of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: , , , | 4 Comments »

Appropriate sequencing of treatments among men with advanced prostate cancer

Posted on September 25, 2012 by Sitemaster

Whether a man is initially diagnosed with metastatic prostate cancer or progresses to have metastatic disease over time (after failure of standard first-line therapies), sooner or later they are all going to need — in consultation with their doctors — to decide on “the best” way to manage their progressive disease through sequential or concurrent use of a number of recently approved agents (always assuming that cost and access are not determining factors). … READ MORE …

Filed under: Uncategorized | Tagged: , , , , , , , , | Leave a Comment »

“Novel drugs enhance — but complicate — prostate cancer treatment”

Posted on September 24, 2012 by Sitemaster

An article with the above title appears in a new issue of The ASCO Post, and is based on a recent presentation by Dr. William Oh (of Mount Sinai School of Medicine, New York) at a “Best of ASCO” educational meeting held in Boston earlier in the year. For those trying to understand how to think about future opportunities for the use of abiraterone acetate, enzalutamide, and radium-223 in advanced and metastatic forms of prostate cancer, this overview may be helpful.

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 7 Comments »

Future development of abiraterone acetate in treatment of prostate cancer

Posted on August 15, 2012 by Sitemaster

Just as we have provided a recent update on the future potential of enzalutamide (MDV3100) in the treatment of prostate cancer, the following offers an update on the future potential of abiraterone acetate (Zytiga®). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Treatment | Tagged: , , | 1 Comment »

Abiraterone approved for clinical use in Scotland

Posted on August 13, 2012 by Sitemaster

As previously projected, the Scottish Medicines Consortium has now approved the clinical use of abiraterone acetate, making the drug available for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after failure of treatment with docetaxel-based chemotherapy throughout the United Kingdom.

Filed under: Drugs in development, Management, Treatment | Tagged: , | Leave a Comment »

Next Page »
Follow

Get every new post delivered to your Inbox.

Join 832 other followers